AxoGen, Inc. CEO Karen Zaderej to Discuss AxoGen’s Growth, Nerve Injuries and New Options for Nerve Repair on “The Big Biz Show”

Share Article

Interview Airs March 20, 2015, Hosted by Bob "Sully" Sullivan, 2:00pm ET/11:00am PT/1:00pm CT

AxoGen Logo

AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Chief Executive Officer Karen Zaderej will be interviewed on BizTalkRadio’s “The Big Biz Show” hosted by Bob “Sully” Sullivan. In this exclusive interview, Ms. Zaderej will discuss the Company’s growth and large market opportunity for its portfolio of peripheral nerve repair solutions which offer alternatives to patients who require surgical repair of peripheral nerves due to injury and trauma. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.

Date:         Friday, March 20, 2015
Start Time:     2:00pm ET | 11:00am PT | 1:00pm CT (U.S.)
Network:     BizTalkRadio
Show:         The Big Biz Show         
Host:         Bob “Sully” Sullivan
Live Stream:     http://player.warpradio.com/BizTalkRadio/index.php

About The Big Biz Show
Sully is a Nationally Syndicated Radio/TV Personality who has something to say about all things in the World of Business! Monday - Friday 9am - 12pm PT / 12pm - 3pm ET. "The Big Biz Show" is named in the TOP TEN Financial Radio Talk Shows by TALKERS Magazine.

About BizTalkRadio
BizTalkRadio is the home for your business. Whether you're an entrepreneur, small business owner or just managing your family's assets, BizTalkRadio can help. Small business generated 64% of all new jobs in the last decade. There are more than 30 million small businesses and 15 million home-based companies in the United States. BizTalkRadio is the only network committed to original, educational and compelling programming about real people succeeding in business.

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

For more information about AxoGen or to sign up for our news alerts, please visit http://www.AxoGenInc.com.

Cautionary Statement Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, market size, product development, product potential, or regulatory activity. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lee Robert "Bob" Johnston Jr, CFO
AxoGen, Inc.
+1 386.462.6856
Email >

Matt Bird
1800 PR
646.401 4499
Email >
Visit website